Linked Life Data

14583740

Source:http://linkedlifedata.com/resource/pubmed/id/14583740

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-12-24
pubmed:abstractText
This pilot study was undertaken to estimate the acute antipsychotic effect size and side effect propensity of risperidone and olanzapine in the pediatric population, in comparison to haloperidol, a conventional antipsychotic with established efficacy. Risperidone and olanzapine are widely used as first-line treatments to ameliorate psychotic symptoms in youth, but their abilities to specifically treat children and adolescents presenting due to psychotic symptoms have not been rigorously studied. Subjects, selected because of prominent positive psychotic symptoms, were randomly assigned to double-blind, parallel treatment with risperidone, olanzapine, or haloperidol for 8 weeks. The primary outcome was reduction in the Brief Psychiatric Rating Scale for Children total score from baseline to termination. An exploratory, descriptive analysis was done to compare the three treatments. A total of 50 patients, 8-19 years, participated. All treatments reduced symptoms significantly with p-values (corrected for multiple comparisons) of 0.0018 for each of the atypical agents and 0.012 for haloperidol. In all, 88% of subjects treated with olanzapine, 74% treated with risperidone, and 53% treated with haloperidol met response criteria. The primary side effects observed in all patients were mild to moderate sedation, extrapyramidal symptoms, and weight gain. Risperidone and olanzapine acutely reduced psychotic symptoms in this pediatric sample. Exploratory comparisons indicate the magnitude of the antipsychotic response with these atypical agents is comparable to that observed with haloperidol. However, youth treated with risperidone and olanzapine experienced weight gain and extrapyramidal effects that appear more prevalent and severe than reported in adults.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0893-133X
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-45
pubmed:dateRevised
2011-5-18
pubmed:meshHeading
pubmed-meshheading:14583740-Adolescent, pubmed-meshheading:14583740-Antipsychotic Agents, pubmed-meshheading:14583740-Benzodiazepines, pubmed-meshheading:14583740-Child, pubmed-meshheading:14583740-Dose-Response Relationship, Drug, pubmed-meshheading:14583740-Double-Blind Method, pubmed-meshheading:14583740-Drug Therapy, Combination, pubmed-meshheading:14583740-Female, pubmed-meshheading:14583740-Haloperidol, pubmed-meshheading:14583740-Humans, pubmed-meshheading:14583740-Male, pubmed-meshheading:14583740-Pilot Projects, pubmed-meshheading:14583740-Pirenzepine, pubmed-meshheading:14583740-Psychiatric Status Rating Scales, pubmed-meshheading:14583740-Psychotic Disorders, pubmed-meshheading:14583740-Risperidone, pubmed-meshheading:14583740-Time Factors, pubmed-meshheading:14583740-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
pubmed:affiliation
Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7160, USA. Lsikich@med.unc.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't